– New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of the TLR9 agonist, SD-101, in metastatic uveal melanoma, consistent with an earlier presentation from pancreatic adenocarcinoma trial –– Median Progression-Free Survival was 1.
– New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of the TLR9 agonist, SD-101, in metastatic uveal.
– New data from PERIO-03 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of a TLR9 agonist in pancreatic tumors –
.
TriSalus Life Sciences®? Inc. announced initial positive safety and feasibility data from a Phase 1 trial at the Society of Immunotherapy for Cancer 2023 Annual Meeting. TriSalus is studying an.
TriSalus Life Sciences® Inc., , an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced.